Key facts
as of Oct 2026- Developer of a ribonucleic acid (RNA) editing platform designed for healthcare professionals.
- AIRNA is valued at approximately $339.0M as of Oct 2026 (last reported valuation).
- It has raised $245.0M; the latest was Early Stage VC ($155.0M) in Mar 2025.
- Notable investors include Alexandria Venture Investments, ARCH Venture Partners, Venrock, Forbion, RTW Investments — 13 tracked in total.
- Status: Privately Held (backing).
Last reported valuation
LOW confidence$339.0M
AIRNA's last reported valuation, Mar 2025. Nothing priced has surfaced since.
Free account
More of AIRNA with a free account
- ·The complete investor list: 13 names
- ·Watch AIRNA: the Monday email on marks, rounds and moves
Create free account
No card required
Funding rounds
No rounds on record
No funding rounds for AIRNA are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Pro members can request priority coverage with a 48-hour turnaround.
About AIRNA
Developer of a ribonucleic acid (RNA) editing platform designed for healthcare professionals. The company's platform is developing RNA editing therapeutics created to maximize therapeutic properties and address novel targets, enabling patients to get a cure for rare and common diseases.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2021
- Employees
- 50
- Website
- airna.com/
- Ownership
- Privately Held (backing)